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Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million
people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life.
Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil,
there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic
review critically addresses the various methodologies used in original research around the world in the last decade on the subject,
showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information
for public health agents is provided.
1. Introduction
Health and the economy are related intrinsically.The purpose
of the studies on the costs of diseases is describing them, esti-
mating costs, comparing established programs, and project-
ing these costs based on clinical, demographic, epidemiolog-
ical, and technological factors. In fact, over the past decade,
there has been a growing number of studies, which are pre-
sumed to be valuable decision tools, because the limited
amount of resources must be used rationally and efficiently
as not to miss opportunities to improve overall population
health [1].
In neurodegenerative diseases, such as Parkinson’s disease
(PD), whose prevention is still impossible, the burden borne
by society, whether it is financial, social, or even psychologi-
cal, is often heavy. Being the secondmost prevalent neurode-
generative disease worldwide, it generally affects individuals
between 40 and 50 (late-onset PD) [2, 3], compromising
their productive life and aging. As such, research needs to be
directed to reducing their costs.
Studies on disease costs may have several approaches,
such as economic assessment, epidemiological design, or
even type of cost involved, as well as the viewpoint of
defining resource use strategies. The diversity in methods is
a significant factor why cost estimates differ between studies,
opening the discussion about which public policies are most
appropriate for PD.
This systematic review provides introductory concepts on
the types of studies on costs and analyzes results in selected
articles critically, highlighting the benefits and limitations
of their methods. Moreover, this study identifies the most
common studies regarding DP costs worldwide over the past
10 years, showing possibilities for studies being carried out in
Brazil, where there is a lack of this type of analysis because
most studies only involve the clinical aspects of the disease.
2. Methodology
In March 2016, two online bibliographic information services
were accessed—SCOPUS and PubMed—with the aim of
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Table 1: Types of economic evaluation and their main characteristics.
Type of economic analysis Costs Advantages Disadvantages
Cost minimization
(CMA) Monetary This technique only measures costs
It does not describe results, and it has little
applicability to health
Cost-effectiveness (CEA) Monetary It allows comparisons between health programs Difficulty in comparison of results
Cost-benefit (CBA) Monetary
This analysis allows comparisons between
strategies because it works with the same
monetary unit
Difficulty of valuing human life
Cost-utility (CUA) Monetary This analysis considers the level of well-beingand preferences of the individual The scales of measurement of quality are arbitrary
selecting original articles about the cost of PD over the past
decade.
The following terms were used for access: (parkinson
disease) AND TITLE-ABS-KEY (economics) OR TITLE-ABS-
KEY (costs of illness) OR TITLE-ABS-KEY (health expendi-
tures) OR TITLE-ABS-KEY (cost effectiveness analysis) OR
TITLE-ABS-KEY (cost benefit analysis) ORTITLE-ABS - CUT
(cost utility analysis) OR TITLE-ABS-KEY (cost minimiza-
tion analysis) OR TITLE-ABS-KEY (direct costs) OR TITLE-
ABS-KEY (CB costs) OR TITLE-ABS-KEY (out of pockets)
AND DOCTYPE (air OR re) AND PUBYEAR > 2004
AND (LIMIT-TO (LANGUAGE, “English”)) AND (LIMIT-
TO (DOCTYPE, “air”)).
Thismethod identified 522 papers.The inclusion criterion
was that articles refer to costs related to this disease in general
and/or regarding the use ofmedication. Papers that compared
procedures and/or medicines, dealt with specific therapies,
as well as PD surgeries, or were related to patient caregivers
or already selected papers but were neither applicable to the
research nor available to access were excluded. Revisions
were also not selected (380 papers were excluded because of
the title, for not being compatible, having been duplicated,
and/or being reviews). Once the first levels of inclusion were
satisfied, 142 papers were selected for reading the abstract.
Although 35 of these had a suggestive title, that is, they did not
tackle general costs of disease exclusively, 107 were separated
for complete reading, and 30 met the criteria for research
(Figure 1).
2.1. Basic Concepts of Health Studies. The determination of
the costs of a disease facilitates learning what its burden to
society is, assessing its degree of efficiency, andunderstanding
how the market tends to organize itself regarding certain
values [4].
2.1.1. Economic Assessment. The basic function of any eco-
nomic assessment is to identify, measure, value, and compare
the costs and consequences of alternative proposals [4–8].
In this case, four techniques are possible (Table 1):
(1) Cost-Minimization. Cost-minimization is the least used
technique, because it only compares costs of interventions
that produce the same outcomes with different costs. For
chronic diseases, such as PD, there are no studies using this
type of analysis.
PubMed/MedLine
125 papers
Scopus
397 papers
20 duplicated papers
502 papers 360 papers excluded not
applicable/title
142 papers to read the
abstract only
35 papers excluded after
reading the abstract
77 papers excluded
after being read
30 papers selected for
review
107 papers to be read
entirely
Figure 1: Search, selection, and inclusion of papers for critical
analysis of studies on economic PD evaluation in online platforms.
(2) Cost-Effectiveness. Cost-effectiveness is the technique
most used in literature, which assesses the impact of different
alternatives that bring better results with lower costs; these
are always comparative and explicit and designed to select the
best option to achieve what is perceived in clinical practice.
(3) Cost-Benefit. This analysis determines whether a new
health technology or intervention generates net benefits to
society. However, due to its difficulty, complexity, and contro-
versies in valuing human life and certain health conditions in
monetary terms, this analysis is rarely found in the literature.
(4) Cost-Utility.This analysis assesses the impacts on survival
and quality of life, which are determining criteria to judge the
effects of strategies in health care, that is, the level of well-
being and preferences of the individual.
2.1.2. Study Designs. The epidemiological study designs
define how the research will be performed in relation to
adopted method [9–13]. The most discussed study designs in
PD research are as follows (Table 2).
(1) Prevalence and Incidence. The prevalence estimates the
number of deaths, hospitalizations, prevention, and research
attributable to a disease in a given period (usually a year),
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Table 2: Main study designs on costs.
Approaches Description Advantages Disadvantages
Prevalence
Frequency measure
It evaluates all existing cases in a
given period
Ample results
Specific policy planning
Fast study and recommended for
chronic diseases
Considered weak at estimating
the risk of developing disease
Incidence
Frequency measure
Assesses the number of new
cases in a given period
Implementation of measures to
reduce new cases
It is used more for acute diseases,
since it estimates the risk of
developing the disease
Not recommended for chronic
diseases
Top-down
It measures the proportion of a
disease attributed to several risk
factors. It involves a study
directed from total to lower levels
When the scope of study is well
understood
More comprehensive, it hampers
the study on the details of the
disease
Bottom-up
Related to the unit costs of inputs
used. It involves the study
directed from individual levels to
the total.
More detailed Risk of double counting
Prospective
Temporal study, performed
during disease. Probes the effect
through the cause
Used in chronic diseases Time-consuming and expensive
Retrospective
Temporal study performed with
preexisting data.
Probes the cause through the
effect
Quick and cheaper Risk of memory bias
Econometric Comparison of groups
Minor amount of data required
Cost difference between the two
populations
Long study, requiring that the
control group be paired to the
study group
Markov models
Stochastic process
Used in prospective studies.
Patients stratified in stages of
disease
Dynamic model aiming at
studying the transition from one
stage to another, evaluating the
costs of each step
Transition of stages is
independent, without
considering the previous one
to subsequently estimate the costs incurred by these conse-
quences. Incidence refers to the number of new cases in a pre-
defined period, and it foresees the associated costs from the
onset of the disease until its disappearance (usually cure or
death), through a rough projection of the flow of these values.
Studies on prevalence display greater results than inci-
dence ones, for diseases are usually long-term sequelae, as is
the case of PD, and they are of great importance in planning
specific policies on certain diseases when their economic
burden was underestimated. Therefore, they can identify
the main components of current expenses and uncharged
resources.
(2) Top-Down andBottom-Up. Top-down approaches are nor-
mally used in prevalence studies, when the expenses of a dis-
ease are widely known from national or regional statistics. In
bottom-up studies, cost estimates are more detailed. The data
depend on the scope of the study, and they are intrinsically
related to the unit costs of inputs used, through interviews,
questionnaires or chart review, and assessment of individual
cost. The average cost per person is then obtained by means
of the number of times the service was used and the number
of people with the disease. Although bottom-up studies are
more complete when it comes to resources and more precise
regarding patient selection, they run a high risk of double
counting costs (e.g., if a patient has more than one disease
and costs of comorbidities are confused and/or grouped).The
majority of studies with PD adopt this approach.
(3) Prospective and Retrospective Approaches. There is a tem-
poral relationship, where in prospective studies the relevant
events have not happened yet, that is, studying the patient
over time, formalizing a system of data collection focused on
the purpose of the research, such as questionnaires designed
specifically for patients and/or their caregivers, where every-
thing is recorded in “real time.” In retrospective studies, all
events had already occurred when the study was initiated.
They are usually employed in long-term chronic diseases, as is
the case of PD. In this case, research efficiency can only be
possible with enough observational datasets. It would be best
if the data were stored electronically to minimize memory
bias due to omission of facts or values.
(4) Econometric Approaches. Econometric approaches esti-
mate differences between groups. One of the groups has the
disease and the other does not; however, both have the same
characteristics, which are assessed by several regression anal-
yses involving demographic factors such as sex, age, marital
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Table 3: Classification of costs.
Types of costs Description
Direct medical Directly related to the disease. Hospitalization, medication, medical appointments,treatments, laboratory tests, and diagnosis
Direct nonmedical Directly related to the disease. Transport, domestic modifications, food
Indirect
Loss of productivity: partial, temporary, or permanent
They may affect the patient and/or caregiver
Early retirement
Intangible Psychological and psychosocial and costs, difficult measurement
Personal
Costs incurred by the patient and/or their family, when there is no support from
private and/or public health care. Private consultations, medication, treatments, and
domestic modifications. Linked with direct costs
status, ethnicity, relationship between patient and caregiver,
housing, and duration of the disease.
(5)MarkovModels.Markovmodels are used in several studies
of chronic diseases, when patients are studied over time, and
they are stratified according to disease scale. In the case of
PD, the scale of Hoehn and Yahr (it assesses the degree of
disability due to the disease in scores) is key to building this
model.These are typically prospective studies, proposing cost
increases with disease severity.
Several approaches may be featured in the same study;
that is, we may have a retrospective, prevalent, and bottom-
up study, for instance, because its purpose, most of the time,
is to maximize the content of information, contributing to
enriching knowledge.
2.1.3. Classification of Costs. The costs of a disease are
typically stratified as follows [4, 7, 10, 14] (Table 3).
(1) Direct Costs. Direct costs are related to the disease and its
equation; their charges may concern public administration,
insurance companies, the patient, the patient’s family, or even
a combination of all or some of these determinants. The
estimates of direct costs associated with chronic diseases are
higher than those associated with acute and communicable
diseases, on the condition that better treatments andmethods
of prevention are adopted. This group can be divided into
direct medical costs and nonmedical ones, although not all
studies adopt this division.
(2) Indirect Costs. Indirect costs refer to the loss of income
and/or productivity; they are caused by disease. Additionally,
they can incur costs to both the patient and the employer.
Depending on the disease, this lossmay be partial, temporary,
or permanent, and it may be restricted to the patient and/or
caregiver (as in the case of advanced stage PD), frequently
leading to early retirement. If there is a possibility of returning
to regular activities, this disease may not occur on the same
productivity level as before, or lead to frequent absences
(absenteeism), incurring additional costs, such as loss of
promotions.
(3) Intangible Costs. Intangible costs are virtually impossible
to measure, since they incur psychological and psychosocial
costs imposed to the patients, their family, and acquaintances
due to the disease, as well as pain, behavioral changes, and
everyday activities. They depend on the perception that the
patient’s health problems lead to social consequences, such as
isolation.
(4) Personal Costs. Personal costs are the costs borne by
the patient and/or their family and friends due to consulta-
tions with health professionals, medication, laboratory tests,
domestic adjustments, locomotion resources, and the need
for home care. Depending on the country, these costs, also
called copayments, are borne by the government, health
insurance, or religious or private health institutions. Some-
times, these payments are also designated as direct costs
because they are associated with the disease. They may be
redeemable or not, implying an additional expense to the
patient, who has to spend a certain amount of money in
advance.
2.1.4. Perspectives. Who bears the costs related to the pro-
gram defines which costs are included for analysis [6, 7, 10]
(Table 4).
(1) Industry (Human Capital). The industry bears the costs
due to absenteeism or loss of productivity, and early retire-
ment due to the disease.
(2) Society. A more comprehensive perspective considers all
costs related to the program, regardless of who will pay
the expenses (patient, government, or insurance companies).
This approach is thought to be the most appropriate to sup-
port health-related decisions. Most research on PD addresses
this perspective, although some studies include more than
one viewpoint.
(3) Patients and Their Family. Costs are borne by the patient
concerning appointments, transport used for his treatment,
purchase of medication, expenses with caregivers, domestic
changes, and so on.
(4) Programs, Public Health, and/or Insurance Companies.
When there is a need to identify all the inputs related to the
disease, for which monetary value explains the base period
and the form of assessment used should be assigned, this
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Table 4: Description of the main perspectives used in cost studies.
Perspective Description
Industry Related to human capital. Considers the individual as an investment target
Society More common in the literature. It is comprehensive and based on health-relateddecisions. It represents the public interest
Patient/family Less common, only addresses the patient’s and their family’s costs
Public/private health care To identify and quantify all inputs used in the production of the service/procedure.Important to form the cost of illness
perspective is highly likely to underestimate the cost of
disease, especially when greater profit or lower production
costs are targeted.
2.2. Studies on the Socioeconomic Impact of PD. Although PD
affects more than four million people worldwide [15], little
is known about their progression rates, the costs of medical
care, and themanagement of resources specific to this disease
[16]. In Brazil, although its notification is not compulsory,
unofficial data estimate 220,000 PD sufferers. Considering
local records of patients with PD, in a study conducted in the
city of Bambuı´,MinasGerais, it was found that 3% of the pop-
ulation above 64 had the disease, a result similar to the preva-
lence rates found in elderly studies in European and Ameri-
can countries and slightly above the rates in Eastern countries
[17].
PD was considered among the most prevalent and costly
diseases of the brain, being the fourth most expensive second
study in 28 European countries [18]. However, the level of
socioeconomic development, budget availability of health
systems, and culture of each country or region determine
research methodologies, which are directed to a subset of
expenses, using only a few components and all expenditure
resulting from a disease, which would be practically impos-
sible. Therefore, there is no one method more or less appro-
priate for this type of study, as the costs of PD in all countries
involved cannot be compared and the information cannot be
simply transferred from one country to another without
having any evidence to support the use of the data.
Over the past decade, there has been a significant increase
in the number of papers related to costs of diseases. Figure 2
shows the evolution for PD, between 2005 and February 2016,
with a higher concentration between 2011 and 2013, triggered
by the need to investigate the values involved in the cost of this
disease. The demographic transition is a reality, and health
managers need data that can enable their strategies towards
public policies.The graph shows the 522 identified papers (125
Pubmed, 397 Scopus) and the 30 selected among them for this
review.
3. Discussion
Thepapers selected for this review are summarized in Table 5.
The PD cost may be very different from one country to
another. Nonetheless, themonetary value of the year inwhich
the study happened should be considered. All values were
converted to US dollars ($) and daily, quarterly, or half-yearly
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Figure 2: Number of publications on PD costs over the past 10 years.
Scopus = 397 papers; Pubmed = 125 papers; Selected = 30.
results were converted to annual. Only one article had values
by period of life [19], and another took into consideration
those 40 to 79 years of age [20].
Practically, all articles used the general costs of the
disease, without naming the type of economic evaluation.
Only one article [21] referred to the burden of disease as
DALY (disability-adjusted life in years), suggesting the use of
cost-utility.
Because there is no way of implementing measures so as
to reduce new cases, the most appropriate model for PD costs
may be developed from prevalence studies. They are con-
ducted when diagnosis has already been established, obtain-
ing ample results, and are to conduct than incidence ones,
which demand rigorous criteria for diagnosis. In this review,
we identified 20 papers that followed this line of research (see
Table 4).
The use of questionnaires, suggesting a bottom-up
approach, is common practice found in the research reviewed
here, although not all of them described the design. The
unit value of the inputs used is more easily acquired than
full reports obtained from large databases in top-down
approaches, although at least six papers suggest the use of this
approach for studying large samples [22–27].
Since it is a disease with long survival, retrospective
studies are the most common for PD, despite the bias of
memory that can be generated depending on the retroactive
period. In reviewed articles, 12 authors (see Table 4) opted for
a prospective study with patient monitoring. Despite being
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lengthy and expensive, some studies usedMarkovmodels [19]
or econometric studies [28, 29] with cohorts, for example.
The aforementioned chosen variables are related to the
purpose of the study, but, in general, we observed that 20 (see
Table 4) out of 30 papers opted for the total cost of the disease,
including direct, indirect, and/or personal costs. In one of the
studies [20], however, indirect costs were only considered,
from the perspective of insurance companies and human cap-
ital, whereas, in another [21], the aim was to evaluate intan-
gible costs alone through lost years of life. Similarly, three
studies concentrated only on medication costs [25, 30, 31].
Among direct costs, themost common variables analyzed
in most studies were medication, hospitalizations, outpatient
visits, auxiliary treatments, home care, transport, and special
equipment. Not all studies divided the direct costs into
medical and nonmedical (Table 3). In one of the studies, even
dental care provided to patients was assessed [29].
Regarding indirect costs, most studies are related to the
patient and/or the caregiver in terms of loss of productivity,
early retirement, and sick leaves (medical certificates). As
for personal costs, they consider informal care, copayment
treatments, drugs, and equipment.
The society costs are the most studied, the society being
themost affected regarding allocation of resources. Only four
studies assessed this prospect from the patient’s point of view
[27, 32–34].
Clarity is needed in the way data and/or results are
expressed, which may generate uncertainty or confusion in
the conclusion of a study. For instance, one of the studies [35]
does not provide a clear cost of PD, and groups are very strat-
ified and only the differences between them are highlighted.
Moreover, albeit the many variables analyzed, important
components were not assessed, such as auxiliary treatments.
On the other hand, another study [20] does not enlist
which direct cost components were used. As such, statistical
analyses must be well established, so that other studies can be
replicated if necessary. In this review, some studies did not
provide that [25, 31, 36].
Many authors have chosen to direct certain types of costs
towards one category, which reinforces the uniqueness of
each study. One author [37] argued that informal care should
be placed with indirect costs, but with direct nonmedical
ones, based on the fact that if home care is not provided by
the family, professional care would be needed.
The fact that the same cost component is classified in
different categories can have a strong influence on the final
results, not considering the values set by the inputs in each
country. In a study conducted in Russia [37], for example,
direct costs accounted for 67% of total costs, while indirect
ones accounted for 33%. Besides, in a study in Singapore [38],
direct costs were 38.5% and indirect ones 61.5% of the total
cost. Another author states [39] that costs were distributed
as 35.7% direct, 29.4% as direct nonmedical costs and 34.9%
as indirect. In this study, we have verified that the value of
consultation with a specialist in the Hungarian public health
care system costs around $7, while in the UK [33] this value is
approximately $225.
Issues related to health insurance also influence the
comparison of studies greatly and must be considered. For
example, in India, a study [36] revealed that only 7.4% of
patients are covered by health insurance, and, unlike most
studies reviewed, the cost of PD treatment is very low, at
around $707 per year, since most of the expenses are covered
by the patients and their family. Conversely, in the UK [33],
maintaining virtually the same research approach, a final
value of around $20,000 a year was calculated. In Japan, on
the other hand [40], a study found a value of around $6,000
per PD patient, where the health insurance covers 100% of the
population. Depending on the patient’s income or age, he/she
contributes 10% to 30% to medical costs.
There are some other factors that certainly affect the
results obtained: samples ranged from small cohorts (𝑛 = 12)
[28] to large populations (𝑛 = 630,000) [22], some studies [41,
42] have excluded from their samples patients with advanced
PD (Hoehn & Yahr 5), and others [19, 43] assessed not only
PD, but also its complications and/or comorbidities.
Finally, with regard to the revised articles of this manu-
script, we could suggest an instrument as a guideline to deter-
mine PD-related costs even though several methodologies
and different variables could be taken into account for each
particular scenario. Therefore, prospective studies would
be the ideal methodology, but cross-sectional, retrospective
ones, with a bottom-up approach from the perspective of
society, could be more feasible. The questionnaire to obtain
data could be divided into the following parts:
(1) Clinical, social, demographic, and economic issues of
the patient;
(2) Medical and nonmedical direct costs;
(3) Indirect costs;
(4) Personal costs (including caregivers).
The most common variables found in the literature used
to determine the costs of PD, depending on the scope of the
study, are shown in Table 6.
4. Conclusion
The concepts mentioned in this review do not aim to finalize
the discussion on health economics tackling the costs of
neurodegenerative diseases, such as PD, but only to allow
access to introductory concepts of these assessments, so that
the reader can contextualize the articles analyzed here.
The very definition of studies on costs of disease suggests
limitations, as the articles here reviewed displaymethodolog-
ical heterogeneity regarding PD costs, and this variation is
an important factor that should receive more attention in
literature. Unlike Alzheimer’s disease, which has a validated
instrument to determine the costs of illness [49], PD presents
considerable problems in its analysis, since evaluations and
comparisons are made between individual studies. If there
were a standardized and validated instrument, the data costs
would be more reliable and transparent and there would be
rational allocation of resources and better collection of data
for cost analysis and efficacy.
We observed that there is no standardization of terminol-
ogy used for the definition of costs, or even unanimity in the
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Table 6: Most common variables found in the cost studies of Parkinson’s disease.
Patient/disease Direct medical cost Direct nonmedical cost Indirect cost Out-of-pockets
Age Hospitalization Ancillarytherapy/rehabilitation Retirement Transportation
∗
Gender Pharmacotherapy(PD and comorbidities) Home Care
∗ Retirement premature Special food
Marital status Outpatient visit Transportation∗ Sick leave Laundry
Instruction Diagnostics Special equipment∗ Working days loss of thepatient Home Care
∗
Working status Nursing home Home modification∗ Working days loss of thecaregivers Caregivers
Duration of PD Copayments∗ Productivity loss Special equipment∗
Comorbidities Loss of leisure time Home modification∗
H & Y stage1 Private health plans
UPDRS2 Copayments∗
PQD-393
MMSE4
1Hoehn & Yahr scale of disability/2Unified Parkinson’s Disease Rating Scale/3Parkinson’s Disease Questionnaire–39 (quality of life)/4Mini-Mental State
Examination.
∗Variables that may be in more than one cost type.
identification of categories because a variable can be found in
different classifications, depending on the criterion used by
the researcher, which may underestimate the total cost of the
disease.
On the other hand, there is no one perfect research
methodology covering a single answer for all solutions.
Sometimes, certain types of studies aremore appropriate than
others. There are several limitations that must be discussed
and related to, such as the methodological problems, and
the validity of their assumptions can differ because they may
introduce bias in analysis in favor of a variable, lack of interest
in its assessment, or even lack of information. Therefore,
researchers must be careful with the source of their data and
the method used for performing the calculations, so that
their research can be replicated and validated, since there
is no specific instrument for the assessment of PD costs.
A limitation also deals with the funding sources of studies,
which may be from government sources, insurance compa-
nies, or pharmaceutical industries, for example, generating
important biases that also need to be addressed. It is necessary
to define useful metrics for public health and private ones
for managers of health, employers, insurance companies, and
even patients themselves, because, without this agreement,
the work of researchers and the funds invested shall remain
uncertain and inconsistent.
Nevertheless, if the evidence obtained is of good quality
in terms of transparency, there is quality and credibility in the
data completeness of the documentation. Overall, if they are
relevant to health care [50], these studies contribute to a better
allocation of resources that are not related to savings but eval-
uate the efficiency, effectiveness, and safety of interventions.
The age group that the PD affects, if well attended to, can
experience “healthy aging,” with a good quality of life and
preserve its autonomy for longer, thus reducing its cost to the
state and society.
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